Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/23225| Title: | CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: results of the HE22A99 trial of the Hellenic Cooperative Oncology Group |
| Institution and School/Department of submitter: | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής |
| Keywords: | Adolescent,Adult,Aged,Aged, 80 and over,Antibodies, Monoclonal/administration & dosage,Antibodies, Monoclonal, Murine-Derived,Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use,Cyclophosphamide/adverse effects/therapeutic use,Epirubicin/adverse effects/therapeutic use,Female,Humans,Lymphoma, B-Cell/drug therapy/pathology,Lymphoma, Mantle-Cell/drug therapy/pathology,Lymphoma, Non-Hodgkin/*drug therapy/pathology,Lymphoma, T-Cell/drug therapy/pathology,Male,Middle Aged,Prednisone/adverse effects/therapeutic use,Vincristine/adverse effects/therapeutic use |
| URI: | https://olympias.lib.uoi.gr/jspui/handle/123456789/23225 |
| ISSN: | 1528-9117 |
| Link: | http://www.ncbi.nlm.nih.gov/pubmed/17921732 |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
